RxDoctor Payments Data

Wayne Panullo, MD

Gastroenterology · New Haven, CTNPI 1679616593

Payments from drug & device makers

$4,612in general payments, 2019–2025

Across 264 payments — averaging $17.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$970
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$680
  • Gilead$409
  • Johnson & Johnson$355
  • Bristol Myers Squibb$197
  • plus $886 from 20 others

What the payments were for

  • Consulting fees$150%
  • Food & beverage$4,52298%
  • Education$752%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,612 in reported general payments places this provider in the 55th percentile of 326 gastroenterology providers in Connecticut.

See all gastroenterology providers in Connecticut

Medicare billing

Part B allowed, 2024
$80,838
Medicare patients
184
Services billed
3,282

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab12$310,169
Humira(Cf) PenAdalimumab23$237,742
LinzessLinaclotide36$34,110
PentasaMesalamine11$16,630
MotegrityPrucalopride Succinate11$15,451
TrulancePlecanatide12$10,938
Mesalamine14$8,564
MovantikNaloxegol Oxalate12$7,327
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates91$5,509
Omeprazole304$4,075
Ursodiol18$3,245
Octreotide Acetate12$2,916
SutabSod Sulf/Pot Chloride/Mag Sulf12$1,975
Esomeprazole Magnesium39$998
Balsalazide Disodium11$947

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$355$310,16912 claims
AbbVieLinzess$1,114$34,11036 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$970$15,45111 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$680$10,93812 claims
Redhill Biopharma Inc.Movantik$45$7,32712 claims
Braintree Laboratories, Inc.Sutab$61$1,97512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 326 gastroenterology providers in Connecticut.

Other gastroenterology in New Haven

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →